The AML M5 blasts exhibited the highest level of background cell death, which in combination with low CD64 profile resulted in no response to H22(scFv)-ETA’ or H22(scFv)-MAP treatment (Figure 2A). Here, FCGR1A is linked to acute myeloid leukemia.